Étiquette : ptsd

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD, Deborah Brauser, Medscape.com, 2021

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD Deborah Brauser Medscape. com, January 18, 2021 Medscape Medical News © 2021 www.medscape.com/viewarticle/944282_print   Repeated intravenous infusions of ketamine provide rapid relief for patients with posttraumatic stress disorder (PTSD), new research suggests. In what investigators are calling the first randomized controlled trial of repeated ketamine administration for chronic PTSD, 30 patients received six infusions of ketamine or midazolam (used as a psychoactive placebo) over 2 consecutive weeks. Between baseline and week 2, those receiving ketamine showed significantly greater improvement than those receiving midazolam. Total scores on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) for the first group were almost 12 points [...]

Lire la suite

Reviewing the Potential of Psychedelics for the Treatment of PTSD, Erwin Krediet et al., 2020

Reviewing the Potential of Psychedelics for the Treatment of PTSD Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten International Journal of Neuropsychopharmacology, 2020, 23, (6), 385–400 doi : 10.1093/ijnp/pyaa018 https://pubmed.ncbi.nlm.nih.gov/32170326/   Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not [...]

Lire la suite

PTSD as a mediator of the relationship between trauma and psychotic experiences, Daniela Strelchuk et al, 2020

PTSD as a mediator of the relationship between trauma and psychotic experiences Daniela Strelchuk, Gemma Hammerton, Nicola Wiles, Jazz Croft, Katrina Turner, Jonathan Heron and Stanley Zammit Psychological Medicine, 2020, 1–9. doi : 10.1017/S0033291720004821   Abstract Background : Traumatic experiences are associated with a higher risk of psychotic illnesses, but little is known about potentially modifiable mechanisms underlying this relationship. This study aims to examine whether post-traumatic stress disorder (PTSD) symptoms mediate the relationship between trauma and psychotic experiences (PEs). Methods : We used data from the Avon Longitudinal Study of Parents and Children to examine whether: PTSD symptoms mediate the relationships between (a) childhood trauma and [...]

Lire la suite

Mind Menders: The Future of Psychedelics for Mental Illness, Batya Swift Yasgur, Medscape.com, 2020

Mind Menders: The Future of Psychedelics for Mental Illness Batya Swift Yasgur MA, LSW Medscape.com, November 10, 2020 https://www.medscape.com/viewarticle/940749?nlid=138288_425&src=WNL_mdplsfeat_201117_mscpedit_psyc&uac=292598PZ&spon=12&impID=2682236&faf=1   After a 50-year hiatus, psychedelic drugs are undergoing a research renaissance. Agents including psilocybin, methylenedioxymethamphetamine (MDMA), and others are all under investigation to treat a variety of psychiatric illnesses. Medscape spoke with Roland R. Griffiths, professor in the Departments of Psychiatry and Neuroscience and the Oliver Lee McCabe III Professor in the Neuropsychopharmacology of Consciousness, and director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University, Baltimore, Maryland, to discuss the status of these drugs in the United States and their therapeutic potential. Griffiths: Classic psychedelics are [...]

Lire la suite

Development of Ketamine Administration as a Treatment for Chronic PTSD, Abigail B. Collins et al., 2020

Development of Ketamine Administration as a Treatment for Chronic PTSD Abigail B. Collins, BS; Sarah B. Rutter, MA; and Adriana Feder, MD Psychiatric Annals, 2020, 50, (2), 68-76. doi : 10.3928/00485713-20200109-01   ABSTRACT Posttraumatic stress disorder (PTSD) is a highly prevalent, chronic, and dis-abling condition for which currently available pharmacotherapies are insuf-ficiently effective. Ketamine, which is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a promising and rapid-act-ing novel treatment intervention for this disorder. Findings from a proof-of-concept, randomized, controlled cross-over study of single-dose intravenous ketamine administration (compared to single-dose midazolam) in patients with chronic PTSD suggest that ketamine is associated with rapid improvement in [...]

Lire la suite

Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder. A Systematic Review, Maya E. O’Neil et al., 2020

Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder. A Systematic Review Maya E. O’Neil, PhD; Shannon M. Nugent, PhD; Benjamin J. Morasco, PhD; Michele Freeman, MPH; Allison Low, BA; Karli Kondo, PhD; Bernadette Zakher, MBBS; Camille Elven, MD; Makalapua Motu’apuaka, BA; Robin Paynter, MLIS; and Devan Kansagara, MD, MCR Annals of Internal Medicine, 2020 doi : 10.7326/M17-0477   Background : Cannabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of the union, yet its efficacy in treating PTSD symptoms remains uncertain. Purpose : To identify ongoing studies and review existing evidence regarding the benefits and harms of plant-based [...]

Lire la suite

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder, Emily M. LaFrance et al., 2020,

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder Emily M. LaFrance, Nicholas C. Glodosky, Marcel Bonn-Miller, Carrie Cuttler Journal of Affective Disorders, 2020, 274, 298–304 Doi : 10.1016/j.jad.2020.05.132   A B S T R A C T Background : Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Method : Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses [...]

Lire la suite

Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults : a preliminary study, Christine A. Rabinak, 2020

Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults : a preliminary study. Rabinak CA, Blanchette A, Zabik NL, Peters C, Marusak HA, Iadipaolo A, Elrahal F Psychopharmacology (Berl)., 2020, Mar 11. doi : 10.1007/s00213-020-05499-8. Science/Homme: Le THC peut être utile dans le trouble de stress post-traumatique (IACM 30 mars 2020) Lors d’une étude contrôlée par placebo avec 71 participants, composée de 3 groupes (25 témoins sains, 27 adultes exposés à un traumatisme sans trouble de stress post-traumatique et 19 patients souffrant d'un trouble de stress post-traumatique), de faibles doses de THC ont réduit la réactivité liée à la menace dans une certaine [...]

Lire la suite

A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis, Mallory J. E. Loflin et al., 2019

A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis Mallory J E Loflin, Kimberly Babson, James Sottile, Sonya B Norman, Staci Gruber, and Marcel O Bonn-Miller The American Journal of Drug and Alcohol Abuse, 2019, VOL. 45, NO. 5, 506–513. Doi : 10.1080/00952990.2019.1604722   ABSTRACT Background : With a rise in public pressure to increase veteran access to medicinal cannabis, free cannabis collectives for military veterans are proliferating across the US. Objectives : The aim of the current study was to document which cannabis formulations and routes of administration are chosen by veterans with increased access to cannabis, and to determine [...]

Lire la suite

Psychedelics for Mental Illness: The Evidence to Date, Todd Murphy, 2020

Psychedelics for Mental Illness: The Evidence to Date Todd Murphy Medscape, 12 March, 2020. https://www.medscape.com/viewarticle/926694_print Psychedelic drugs show real promise as treatment for psychiatric illnesses, particularly posttraumatic stress disorder (PTSD) as well as depression and anxiety, new research suggests. A literature review showed completed clinical trials support the efficacy of 3, 4-methylenedioxymethamphetamine (MDMA), commonly known by its street name of Ecstasy, to treat chronic PTSD. The review also confirmed that psilocybin, a compound contained in some species of mushrooms, significantly helped in the treatment of depression and cancer-related anxiety. Other promising, though more preliminary, results suggests that the hallucinogenic drug LSD (lysergic acid diethylamide) and a plant-based brew [...]

Lire la suite